FIELD: biochemistry.
SUBSTANCE: invention relates to the single-domain Ebola VP24 antibody capable of specifically binding to the Ebola VP24 antigen, as well as to use thereof for treating Ebola disease, for preventing the development of Ebola disease, as well as to use thereof for preventing the recurrence of Ebola disease. Also disclosed is an isolated polypeptide capable of specifically binding to Ebola VP24 antigen.
EFFECT: invention enables effective treatment of Ebola's disease.
20 cl, 4 ex, 4 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE-DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS | 2016 |
|
RU2742248C2 |
| SINGLE-DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS | 2016 |
|
RU2741110C2 |
| SINGLE-DOMAIN ANTIBODIES AGAINST INTRACELLULAR ANTIGENS | 2015 |
|
RU2810002C2 |
| SINGLE-DOMAIN ANTIBODY AND DERIVATIVES THEREOF TO LIGAND-1 PROTEIN OF PROGRAMMED CELL DEATH (PDLI) | 2016 |
|
RU2715595C2 |
| SINGLE-DOMAIN ANTIBODIES TO EBOLA VIRUS GP PROTEIN FOR IMMUNOTHERAPY OF EBOLA FEVER | 2015 |
|
RU2644202C2 |
| MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2015 |
|
RU2630304C2 |
| MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2015 |
|
RU2639533C2 |
| MONOCLONAL ANTIBODY, LINKING WITH E-BIR VIRUS GLOBE-PROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2016 |
|
RU2644334C2 |
| VACCINE AGAINST HIV/AIDS | 2010 |
|
RU2475264C2 |
| METHODS OF PURIFYING SINGLE-DOMAIN ANTIGEN-BINDING MOLECULES | 2009 |
|
RU2553214C2 |
